Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Delisting risk
confidence 98%
filed 2026-07-20
The filing discloses a Nasdaq delist determination letter dated July 15, 2026, notifying the Company that its securities will be delisted from The Nasdaq Global Market due to failure to maintain minimum Market Value of Listed Securities ($50 million) under Listing Rule 5450(b)(2)(A), with an additional basis being failure to meet the minimum 400 shareholder requirement. Trading suspension is scheduled for July 24, 2026, unless the Company appeals by July 22, 2026. This is a direct delisting notice under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-20
Item 8.01
The filing discloses a Nasdaq compliance violation under Listing Rule 5250(c)(1) for failure to timely file the Form 10-Q for the period ended March 31, 2026. Although the Company subsequently cured the violation by filing the Form 10-Q on July 16, 2026, the initial non-compliance notification and the cure represent a material delisting risk event. The disclosure of the violation itself—even though remedied—is material to investors as it signals potential operational or financial reporting challenges and demonstrates the Company came within reach of delisting consequences.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-20
Item 8.01
The Company disclosed receipt of a Nasdaq deficiency notification for failure to timely file its Form 10-Q, triggering non-compliance with Nasdaq Listing Rule 5250(c)(1). While the Company submitted a Compliance Plan and trading continues, the filing directly addresses a material delisting risk — the Company faces potential delisting if the Compliance Plan is rejected and it cannot regain compliance. This is a core delisting-risk disclosure under Item 3.01 principles, disclosed here under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-07-20
Item 3.01
SES AI received notice from the NYSE on July 17, 2026, that it failed to comply with Section 802.01C of the NYSE Listed Company Manual because the average closing price of its Class A common stock was below $1.00 over a consecutive 30 trading-day period. The company has a six-month cure period to regain compliance or face potential delisting.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-17
EX-99.1
The press release discloses receipt of a Nasdaq Listing Qualifications Staff Determination Letter on July 14, 2026, notifying the Company that it failed to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days. The Company has been granted a 180-calendar-day compliance period (until January 11, 2027) to regain compliance, with potential for an additional 180-day period if certain conditions are met. This is a material delisting risk disclosure under Nasdaq Listing Rule 5810(b), which requires prompt disclosure of deficiency notifications.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-17
Item 8.01
Sadot Group disclosed that it failed to meet Nasdaq's minimum stockholders' equity requirement of $2,500,000 under Listing Rule 5550(b)(1), with explicit warning that failure to regain and maintain compliance could result in delisting, though management believes recent transactions have restored compliance to over $7,000,000.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-16
Item 3.01
Chart Industries notified the NYSE on July 16, 2026 of the completion of the merger and requested withdrawal of its listing, with plans to file Form 25 for delisting and Form 15 for deregistration.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-16
EX-99.1
The Company received a written notification from Nasdaq on July 14, 2026, stating non-compliance with Nasdaq Listing Rule 5250(c)(2) due to failure to file a Form 6-K containing interim financial statements for the six-month period ended December 31, 2025. The Company has 60 calendar days to submit a compliance plan, with potential extension to 180 days. The notice explicitly states "There can be no assurance that the Company's plan will be accepted or the Company will be able to regain compliance," and the Company will be listed as a non-compliant issuer. This is a clear delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-16
The 6-K discloses that the SEC suspended trading in the Company's securities from June 12–26, 2026, and that Nasdaq subsequently halted trading in the Company's Class A ordinary shares pending satisfaction of an information request. The Company submitted its response on July 10, 2026, but trading remains halted with "no assurance as to when, or whether, trading in the Company's Class A ordinary shares will resume." This is a material delisting risk — the registrant faces a continued listing threat and loss of trading access, which directly threatens investor liquidity and the registrant's capital-raising ability.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-16
EX-99.1
The press release discloses that Cellyan received a Nasdaq notification letter on July 14, 2026 granting an additional 180-day compliance grace period (until January 11, 2027) to regain compliance with the Nasdaq minimum $1.00 closing bid price requirement. The Company must maintain a closing bid price of at least $1.00 per share for ten consecutive business days to avoid delisting. This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq and would materially affect a reasonable investor's assessment of the registrant's status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-16
EX-99.1
The press release discloses a Nasdaq notification that Ohmyhome has failed to maintain the minimum bid price of $1.00 per share required under Nasdaq Listing Rule 5550(a)(2). The Company has been granted a 180-day compliance period (until January 11, 2027) to regain compliance, with potential for an additional 180-day extension if certain conditions are met. This is a classic delisting-risk disclosure under Item 3.01 — the Company faces potential delisting if it cannot restore its share price above $1.00 within the cure period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-16
EX-99.1
CBL International announced a 1-for-13 reverse share split "primarily to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) relating to the maintenance of the minimum bid price per share." This disclosure reveals the company has fallen below Nasdaq's minimum bid price requirement and faces delisting risk absent this remedial action. The reverse split is a direct response to a continued listing rule violation, making this a material delisting-risk disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-16
Item 3.01 discloses that SRX Global has regained compliance with NYSE American listing standards after resolving deficiencies under Section 1003(a)(i) and (ii) of the Company Guide that were previously cited in an October 14, 2025 notice. The removal of the compliance indicator (".BC") and delisting risk is material to investors assessing the registrant's continued trading status and financial viability.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-16
ZyVersa Therapeutics ceased trading on the OTCQB Venture Market and moved to the OTC Pink Limited Market effective July 16, 2026. This represents a downgrade in listing status and is a material transfer of listing that signals potential delisting risk or failure to maintain continued listing standards. The move from OTCQB to OTC Pink is a significant negative development for investor visibility and liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-16
Our Bond, Inc. received notification from Nasdaq on July 14, 2026 that it has failed to maintain compliance with three critical listing standards: minimum bid price of $1.00 per share, minimum market value of publicly held shares of $15 million, and minimum market value of listed securities of $50 million. The company has been granted 180 calendar days (until January 11, 2027) to regain compliance, and Nasdaq will publicly list the company as non-compliant on its website. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-07-16
EX-99.1
Pitanium Limited received a delisting determination letter from Nasdaq dated July 7, 2026, notifying the Company that Nasdaq Staff has determined to delist the Company's securities from Nasdaq pursuant to Listing Rule IM-5101-4. Trading suspension is scheduled for July 16, 2026, unless the Company appeals by July 14, 2026. This is a definitive delisting notice, not merely a risk or warning, making it a material event that directly affects the registrant's continued listing status and investor access to trading.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-16
Item 3.01
Cycurion received a Staff Determination Letter from Nasdaq on July 10, 2026, notifying the company of delisting due to failure to maintain the $1.00 minimum bid price for 31 consecutive business days. The company is ineligible for the customary 180-day compliance period due to a reverse stock split effected within the prior year, with trading suspension expected July 21, 2026 absent a timely hearing request.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-15
EX-99.1
Canaan received written notification from Nasdaq granting an additional 180-day compliance period (until January 11, 2027) to regain compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The Company previously received an initial notification on January 14, 2026, and has now exhausted its first compliance period. This disclosure directly addresses continued listing status and the risk of delisting if the Company fails to meet the minimum bid price threshold during the second compliance period.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 8.01
Atlantic American Corporation disclosed that Nasdaq has notified it of non-compliance with Listing Rule 5250(c)(1) due to delayed filing of its Form 10-K and Form 10-Q. The company has been granted an extension until October 12, 2026 to regain compliance, with explicit warning that failure to do so will result in delisting notification from Nasdaq. This is a classic delisting-risk disclosure under Item 3.01 (though filed under Item 8.01), materially threatening the continued listing of the company's common stock.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 3.01
SemiLEDs received a Nasdaq delisting notice on January 30, 2026 for failing to meet the minimum $2.5 million stockholders' equity requirement under Listing Rule 5550(b)(1). Although the company claims to have regained compliance as of May 31, 2026 with $3.1 million in equity, Nasdaq retains the right to delist if compliance is not evidenced at the next periodic report. This is a classic delisting-risk disclosure under Item 3.01, material to investors assessing the registrant's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 3.01
Following the merger completion, Nuvalent notified Nasdaq of the transaction and requested a halt and suspension of trading in its shares, with delisting from Nasdaq and deregistration under Section 12(b) of the Exchange Act to follow, along with intended filing of Form 15 to suspend reporting obligations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 75%
filed 2026-07-15
The Company announces termination of its ADR program and mandatory cancellation of ADSs, with Class A ordinary shares to trade directly on Nasdaq under a new symbol "QH" effective July 17, 2026. While this is a shareholder-approved listing transition rather than a delisting per se, it represents a material change in the trading venue and security structure (share consolidation at 32,000:1 ratio) that affects how existing ADS holders will hold and trade the underlying shares. The mandatory conversion and consolidation constitute a material restructuring of the equity security and its trading mechanism.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-15
Item 8.01
The filing discloses a Nasdaq minimum bid price compliance issue under Listing Rule 5550(a)(2), which is a delisting risk event. Although the Company ultimately regained compliance by July 10, 2026, the disclosure centers on the notice of non-compliance received on January 29, 2026, and the subsequent resolution. This is a material event affecting continued listing status and would be of significant concern to investors, even though the immediate delisting threat has been resolved.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-15
Item 7.01
LQR House Inc. implemented a 1-for-100 reverse stock split effective July 13, 2026, to regain compliance with Nasdaq's $1.00 minimum closing price requirement for continued listing. The company disclosed this delisting-risk mitigation measure via press release on July 15, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-15
EX-99.1
Zhibao Technology received a Nasdaq deficiency letter for failure to maintain the Minimum Bid Price Requirement (Rule 5550(a)(2)), with closing bid prices below $1.00 per share from May 27 to July 9, 2026. The Company has 180 calendar days until January 6, 2027 to regain compliance, and if it fails to do so, "the Company's Class A ordinary shares will be subject to delisting." This is a material disclosure of delisting risk under Item 3.01 equivalent, as it directly threatens the registrant's continued listing status on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-15
Item 3.01
The filing discloses a notice from the Nasdaq Hearings Panel granting Triller an exception to regain compliance with the Nasdaq Bid Price Rule (Rule 5550(a)(2)) by July 30, 2026. This is a continued listing compliance matter: the Company must achieve a closing bid price of $1.00 or more for twenty consecutive business days or face delisting. The disclosure explicitly references prior delisting proceedings and a remanded matter, establishing material delisting risk under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-15
Item 3.01
SPAR Group received a definitive delisting notice from Nasdaq on July 14, 2026, determining that the Corporation failed to comply with Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule) and Rule 5550(b) (Stockholders' Equity Rule), with delisting effective July 23, 2026, unless the Corporation requests an appeal by July 21, 2026.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-15
EX-99.1
The exhibit discloses that Nasdaq has granted Cheche Group Inc. an additional 180-day extension to regain compliance with the minimum bid price rule (US$1.00 per share), with a new compliance deadline of January 11, 2027. The filing explicitly states: "If the Company does not regain compliance with the Rule by January 11, 2027, it may be subject to delisting from Nasdaq." This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces potential delisting if it fails to meet the bid price requirement within the extended period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-14
EX-99.1
Apollomics announced on July 8, 2026, that it "regained compliance" with Nasdaq's Market Value of Listed Securities (MVLS) requirement after receiving a non-compliance notice on June 18, 2026, for failing to maintain the $35 million minimum. The press release explicitly states "the matter is now closed," confirming resolution of a delisting risk that threatened the company's continued listing on the Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Following the completion of the Ligand Pharmaceuticals acquisition, XOMA Royalty notified Nasdaq to halt trading and delist its shares effective July 14, 2026, and intends to file Form 15 to terminate registration and suspend reporting obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Trinity Capital announced on July 14, 2026, its intention to voluntarily transfer the listings of its common stock and senior notes from Nasdaq to the New York Stock Exchange and NYSE Texas, with trading expected to commence on or about July 27, 2026. This strategic relisting involves changes to ticker symbols and trading venues for both securities.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01
Whitestone REIT notified NYSE on July 14, 2026 of the completion of its acquisition by Ares Real Estate funds and requested cessation of trading and delisting via Form 25. Trading was suspended on July 14, 2026, and the company intends to file Form 15 to deregister under Section 12(g).
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-14
EX-99.1
The press release announces that Jinxin Technology has regained compliance with Nasdaq's Minimum Bid Price Requirement (Listing Rule 5550(a)(2)) after receiving a deficiency notice on January 29, 2026. The company evidenced a closing bid price at or above US$1.00 for 10 consecutive business days from June 26 to July 10, 2026, thereby curing the deficiency and closing the matter. This disclosure directly addresses a delisting risk — the company was previously non-compliant with a continued listing standard and faced potential delisting within a 180-day cure period, but has now remedied that condition.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-14
The Company received notification from Nasdaq on July 13, 2026, granting an extension of 180 calendar days (until January 4, 2027) to regain compliance with the Minimum Bid Price Rule. The disclosure explicitly states that failure to regain compliance by that date will result in written notification of delisting. This is a material delisting-risk disclosure under Item 3.01 equivalent, as it directly threatens the Company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 8.01
Genprex received a Nasdaq delisting notice on June 10, 2026, for failure to maintain the minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has requested a hearing before a Nasdaq Hearings Panel and is implementing a 1-for-22 reverse stock split effective July 16, 2026, to regain compliance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-14
Item 3.01 discloses that on July 8, 2026, SBC Medical Group notified Nasdaq that it would cease compliance with Nasdaq independence rules for board and audit committee membership due to Mike Sayama's departure. On July 10, 2026, Nasdaq formally notified the Company of non-compliance with Listing Rule 5605 and granted a cure period until the earlier of the next annual shareholders' meeting or July 9, 2027. This is a material delisting risk event requiring immediate remediation through appointment of independent directors.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 75%
filed 2026-07-14
The filing discloses a trading halt by NYSE Regulation due to "abnormally low trading price" and explicitly states "the risk that NYSE American may delist our Common Stock" and "the risk that NYSE American may not timely remove any trading halt." While the reverse stock split is the primary action disclosed, the material event driving the filing is the delisting risk and trading halt, which are the triggering circumstances necessitating the reverse split to restore compliance with NYSE American listing standards.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-07-14
EX-99.1
The announcement discloses a 12-for-1 share consolidation effected on July 14, 2026, explicitly stated as undertaken "to ensure the Company's ongoing compliance with Nasdaq Marketplace Rule 5550(a)(2) in order to maintain its listing on Nasdaq." This is a direct response to a delisting risk — the company's share price had fallen below the minimum bid price threshold required by Nasdaq's continued listing standards. The consolidation is a remedial action to avoid delisting, making this a material disclosure of delisting risk and the company's response to it.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 94%
filed 2026-07-14
Item 3.01
D-Wave voluntarily transferred its stock listing from NYSE to Nasdaq, effective July 24, 2026, with trading commencing on Nasdaq on July 27, 2026 under the same ticker "QBTS". The company has met all Nasdaq listing requirements and expects a smooth transition.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 97%
filed 2026-07-13
Item 3.01
BNB Plus Corp. received a definitive delisting determination from the Nasdaq Hearing Panel due to non-compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Trading on Nasdaq will be suspended effective July 14, 2026, with the company transitioning to the OTCQB Venture Market, though the company intends to request a Listing Council Review.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-13
Item 3.01
Esperion notified Nasdaq of the consummation of the merger and requested delisting via Form 25, with the company's shares no longer to be listed on Nasdaq and the company intending to file Form 15 to terminate SEC reporting obligations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-13
EX-99.1
The press release announces that POMDOCTOR has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share under Listing Rule 5450(a)(1), resolving a prior non-compliance notice issued on January 29, 2026. While the announcement is positive (compliance restored), the underlying event—a delisting risk triggered by failure to maintain minimum bid price—is material to investors. The disclosure directly addresses a continued listing rule and the threat of delisting that preceded it, making this a delisting_risk classification focused on the resolution of that material threat.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-13
Item 3.01
Pluri Inc. received a written notice from Nasdaq on July 7, 2026, indicating non-compliance with Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million. The company has been given 180 calendar days until January 4, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-13
Item 3.01
Nasdaq issued a press release on July 10, 2026 stating that Actelis Networks' common stock, suspended from trading on April 10, 2026, would be officially delisted from Nasdaq. The company's stock has transferred to the OTCQB Venture Market. This is a material delisting event that directly affects the registrant's listing status and investor access to the security.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-13
Item 3.03
T3 Defense implemented a 1-for-50 reverse stock split to "raise the per share bid price of the Company's Common Stock above $1.00 per share and bring the Company back into compliance with Nasdaq Listing Rule 5550(a)(2)." This is a direct response to a delisting risk triggered by the stock trading below the $1.00 minimum bid price requirement. The filing explicitly states the company was out of compliance and needed to regain it, making this a material delisting-risk disclosure.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-13
EX-99.1
Gamehaus received a Nasdaq notification that its Class A ordinary shares have traded below the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a 180-day compliance period ending January 6, 2027. This is a classic delisting-risk disclosure under Nasdaq Listing Rule 5550(a)(2). The company faces potential delisting if it cannot regain compliance, making this material to investors assessing the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-10
EX-99.1
Largo received notification from Nasdaq that it is not in compliance with the minimum bid price requirement (Nasdaq Rule 5550(a)(2)) because its closing bid price was below US$1.00 for 30 consecutive business days. The company has 180 calendar days to regain compliance or face delisting. This is a material disclosure of delisting risk that would significantly affect a reasonable investor's assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-10
EX-99.1
Frontier received a written notification from Nasdaq on July 6, 2026, stating non-compliance with Nasdaq Listing Rule 5250(c)(2) due to failure to file a Form 6-K containing interim financials for the six-month period ended December 31, 2025. The company has 60 calendar days to submit a compliance plan, with potential extension to 180 days. The disclosure explicitly states "There can be no assurance that Frontier's plan will be accepted or Frontier will be able to regain compliance" and notes the company will be listed as non-compliant. This is a clear delisting-risk disclosure under Item 3.01 equivalent, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-07-10
EX-99.1
GreenPower announces revocation of a cease trade order (CTO) issued by the British Columbia Securities Commission on July 6, 2026, due to the Company missing Canadian filing deadlines for year-end reports. While the CTO has been lifted, the disclosure of a recent cease trade order and the Company's failure to meet regulatory filing deadlines signals regulatory compliance risk and potential delisting exposure, which is material to investors assessing the registrant's ability to maintain listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-10
Item 3.01
LM Funding received a second notification from Nasdaq on July 7, 2026, confirming the company's common stock failed to regain compliance with the $1.00 minimum bid price rule. Nasdaq granted an additional 180-day cure period until January 4, 2027, after which the company's common stock will be delisted if compliance is not achieved.
View raw filing on EDGAR →